Clinical application of the anti‐human telomerase reverse transcriptase (h TERT ) antibody ( SCD‐A7 ) immunocytochemistry in liquid‐based urine cytology: A prospective, single institute study
Cancer Medicine · 2023
DOI: 10.1002/cam4.5767 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Ji Hye Moon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Telomerase. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Objectives
Urine cytology is the most widely used noninvasive screening tool for urothelial carcinoma diagnosis and surveillance. Although highly specific, urine cytology exhibits suboptimal sensitivity. This study aimed to determine whether hTERT immunocytochemistry (ICC) could be applicable as an ancillary test in routine cytology practice.
Methods
A total of 561 urinary tract samples were initially screened in this study. All of them were prepared using SurePath liquid‐based cytology (LBC), while additional LBC slides were made and subsequently used for hTERT (SCD‐A7) ICC.
Results
From the 561 samples screened, 337 were finally analyzed, all having an adequate cellularity and available follow‐up histology. The hTERT ICC‐positive rate was 95.9% ( n = 208/217), 96% ( n = 24/25), and 100% ( n = 4/4) in cytology samples with high‐grade urothelial carcinoma, carcinoma in situ, and low‐grade urothelial carcinoma subsequent histology. Among the 64 atypical cytology cases histologically confirmed as urothelial carcinomas, 92.2% ( n = 59/64) were immunoreactive to hTERT, whereas the two histologically benign cases were ICC‐negative. 87/90 (96.7%) of the cytology cases confirmed to be benign in follow‐up were hTERT‐negative. The overall sensitivity and specificity of hTERT ICC were 96.3% and 98.8%, respectively (AUROC = 0.963; 95% CI = 0.960–0.967).
Conclusions
The hTERT ICC test exhibited consistent and intense staining in malignant urothelial cells, suggesting its value as an ancillary test in liquid‐based urine cytology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- School of Medicine, European University Cyprus, Nicosia, Cyprus.
- Department of Pathology, Seoul National University Hospital, Seoul, Republic of Korea.
- Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Pathology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, South Korea.
- Center for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
ORCID-Profile: Han Suk Ryu
Förderung
- National Research Foundation of Korea
Zitieren
APA
Moon, J. H., Nikas, I. P., Moon, K. C., Kim, B., & Ryu, H. S. (2023). Clinical application of the anti‐human telomerase reverse transcriptase (h TERT ) antibody ( SCD‐A7 ) immunocytochemistry in liquid‐based urine cytology: A prospective, single institute study. Cancer Medicine. https://doi.org/10.1002/cam4.5767
Vancouver
Moon JH, Nikas IP, Moon KC, Kim B, Ryu HS. Clinical application of the anti‐human telomerase reverse transcriptase (h TERT ) antibody ( SCD‐A7 ) immunocytochemistry in liquid‐based urine cytology: A prospective, single institute study. Cancer Medicine. 2023. doi:10.1002/cam4.5767
BibTeX
@article{Moon2023,
author = {Moon, Ji Hye and Nikas, Ilias P and Moon, Kyung Chul and Kim, Bohyun and Ryu, Han Suk},
title = {Clinical application of the anti‐human telomerase reverse transcriptase (h TERT ) antibody ( SCD‐A7 ) immunocytochemistry in liquid‐based urine cytology: A prospective, single institute study},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.5767}
}
EUVIMED